-
Aimmune Therapeutics (AIMT) PT Raised to $58 at RBC Capital
-
Pre-Open Stock Movers 03/25: (CRIS) (AVYA) (AIMT) Higher; (PTI) (REPH) (AKAM) Lower (more...)
-
Pre-Open Stock Movers 12/20: (AGEN) (TLRY) (PTE) Higher; (DBVT) (ADMA) (SPPI) Lower (more...)
-
DBVT Setback Removes Competitive Risk for Aimmune Therapeutics' (AIMT) AR101 - RBC
-
Aimmune Therapeutics (AIMT) Takeaways From Allergist KOL Call - RBC
-
Aimmune Therapeutics Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
-
Aimmune Therapeutics Announces Closing of Public Offering of Common Stock
-
Aimmune Therapeutics (AIMT) Prices 5.5M Share Common Offering at $32/Sh
-
Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock
-
Aimmune Therapeutics (AIMT) Offers $150M in Common Equity
-
Aimmune Therapeutics Announces Proposed Public Offering of Common Stock
-
RBC Capital Starts Aimmune Therapeutics (AIMT) at Outperform

